To include your compound in the COVID-19 Resource Center, submit it here.

Novartis reports response data for CAR T in DLBCL

Novartis AG (NYSE:NVS; SIX:NOVN) said chimeric antigen receptor (CAR) T cell therapy tisagenlecleucel-T (CTL019) led to a best overall response rate (ORR) of 59% in the pivotal Phase II JULIET trial to treat relapsed or refractory diffuse large B cell lymphoma. The interim data were released in an abstract ahead of next week's International Conference on Malignant Lymphoma in

Read the full 591 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE